Healthcare Global Enterprises
Market cap ₹8,948 Cr
- P/E
- 844.15
- Day range
- ₹570.90 – ₹601.70
- 52-week range
- ₹513.30 – ₹775.00
- Volume
- 1.79 L
- Open
- ₹570.90
- Prev close
- ₹575.60
Latest results · Q2 FY27(consolidated)Revenue ₹732 Cr+13.1%Profit ₹9 Cr-55.2%Margin 1.3%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
HCG in NSE indices and F&O
Research profile
Factor percentiles
Derived metrics
- Earn. yield
- 0.1%
- Graham no.
- ₹75.26
- vs Graham
- -87.4%
- ROE ÷ P/B
- 0.3%
- Magic Formula
- #602
- Piotroski
- 5/6
- FCF yield
- 0.6%
Appears in 3 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Healthcare Global EnterprisesHCG | ₹8,948 Cr | 844.15 | 6.35 | 2.0% | 8.0% | 18.2% | 1.19 | +13.1% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 3h agoHeadlines about Healthcare Global Enterprises from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 225.0
- Price / Book
- 6.64
- ROE (FY26)
- 2.0%
- ROCE (latest year)
- 8%
- Dividend yield
- 0.00%
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- DII
- Public
- FII
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 469.87 | 494.63 | 525.58 | 553.54 | 558.57 | 585.16 | 613.16 | 646.85 | 633.07 | 652.33 | 695.10 | 731.80 |
| Expenses | 391.26 | 402.60 | 434.68 | 451.30 | 470.19 | 479.53 | 505.37 | 523.54 | 523.51 | 527.25 | 572.84 | 598.41 |
| Operating Profit | 78.61 | 92.03 | 90.90 | 102.24 | 88.38 | 105.63 | 107.79 | 123.31 | 109.56 | 125.08 | 122.26 | 133.39 |
| OPM % | 16.7% | 18.6% | 17.3% | 18.5% | 15.8% | 18.1% | 17.6% | 19.1% | 17.3% | 19.2% | 17.6% | 18.2% |
| Other Income | 6.07 | 9.01 | 8.81 | 11.13 | 5.54 | 10.23 | 7.51 | 2.93 | -10.20 | -18.32 | 13.06 | -8.68 |
| Interest | 29.46 | 26.84 | 33.71 | 35.98 | 40.70 | 44.17 | 45.47 | 43.62 | 44.78 | 42.70 | 39.87 | 38.42 |
| Depreciation | 44.16 | 45.98 | 47.01 | 49.74 | 56.52 | 58.07 | 57.91 | 62.80 | 60.65 | 62.81 | 70.42 | 67.80 |
| Profit before tax | 11.06 | 28.22 | 18.99 | 27.65 | -3.30 | 13.62 | 11.92 | 19.82 | -6.07 | 1.25 | 25.03 | 18.49 |
| Tax % | 69.0% | 16.9% | 28.2% | 25.2% | -334.9% | 50.3% | 49.8% | -4.2% | 30.1% | -223.2% | 34.2% | 50.0% |
| Net Profit | 3.43 | 23.46 | 13.63 | 20.68 | 7.75 | 6.77 | 5.98 | 20.66 | -7.90 | 4.04 | 16.46 | 9.25 |
| EPS in Rs | ₹0.41 | ₹1.52 | ₹0.86 | ₹1.28 | ₹0.50 | ₹0.52 | ₹0.34 | ₹1.15 | ₹-0.66 | ₹0.15 | ₹0.92 | ₹0.32 |
From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
-7 days since Mar 2021
0 days since Mar 2021
-36 days since Mar 2021
+28 days since Mar 2021
-35 days since Mar 2021
Strengths, risks & growth
Healthcare Global Enterprises Ltd is engaged in setting up and managing hospitals and medical diagnostic services including scientific testing and consultancy services in the pharmaceutical and medical sector. [1]
Strengths
None flagged by the checklist.
Risks
- Stock is trading at 6.64 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company has a low return on equity of 4.24% over last 3 years.
- Promoter holding has decreased over last 3 years: -7.09%
Compounded Sales Growth
- 10 Years
- +16%
- 5 Years
- +20%
- 3 Years
- +14%
- TTM
- +13%
Compounded Profit Growth
- 10 Years
- +39%
- 5 Years
- +18%
- 3 Years
- -1%
- TTM
- +12%
Stock Price CAGR
- 10 Years
- +9%
- 5 Years
- +19%
- 3 Years
- +19%
- 1 Year
- -19%
Return on Equity
- 10 Years
- -1%
- 5 Years
- +4%
- 3 Years
- +4%
- Last Year
- +3%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 63.77% | 64.21% | 64.21% | 64.21% | 0.00 pp |
| FII | 3.22% | 2.76% | 2.73% | 2.70% | -0.03 pp |
| DII | 18.30% | 18.91% | 19.20% | 20.78% | +1.58 pp |
| Public | 14.71% | 14.15% | 13.86% | 12.32% | -1.54 pp |
Filed with NSE for Sept 2026: promoters 64.21%, public 35.79%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 18.73% (+3.30 pp)- Promoters64.2%
- Foreign institutions2.7%
- Mutual funds18.7%
- Insurance0.9%
- Other domestic institutions1.2%
- Retail5.8%
- Others6.5%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| Nippon India Small Cap Fund | 3.22% | 0.35% | -0.04 pp |
| Nippon India ELSS Tax Saver Fund | 2.56% | 1.56% | -0.11 pp |
| Axis Small Cap Fund | 2.26% | 0.66% | -0.07 pp |
| Franklin India Small Cap Fund | 1.57% | 1.00% | +0.18 pp |
| Axis Flexi Cap Fund | 1.11% | 0.72% | -0.07 pp |
Scorecard
- Performance
- Avg
- Valuation
- High
- Growth
- Low
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
5 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — failed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — passed
- Current ratio improving — passed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — passed
- Asset turnover improving — passed
- Free cash flow
- ₹55 Cr
- FCF yield
- 0.6%
- Cash conversion
- 15.24
- Accruals ratio
- -0.083
- Net debt
- ₹1,489 Cr
- Net debt / equity
- 1.10
- EV / sales
- 3.85
- Capex intensity
- 11.5%
- Revenue CAGR
- 16.1%
- Profit CAGR
- 23.1%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Insider trades
| Person | Type | Shares | Value | Disclosed |
|---|---|---|---|---|
ASHWINI P KAVADIMATTI Designated Person · Pledge Creation | Pledge | 5,000 | ₹34.9 L | 29 Sept 2026 |
ASHWINI P KAVADIMATTI Designated Person · Market Sale | Sell | 500 | ₹3.4 L | 29 Sept 2026 |
Sunu Manuel KMP · Pledge Release | Pledge released | 38,799 | ₹2.8 Cr | 14 Aug 2026 |
Madan Kumar Sampath Designated Person · Invocation of pledge | Sell | 34,970 | ₹2.5 Cr | 12 Aug 2026 |
Sunu Manuel KMP · Invocation of pledge | Sell | 27,000 | ₹1.9 Cr | 11 Aug 2026 |
Bharatsinh S Gadhavi Employees/Designated Employees · Market Sale | Sell | 13,869 | ₹72.0 L | 31 Mar 2026 |
BHAGYA A AJAIKUMAR Promoter Group · Public Right | Buy | 105 | ₹53,760 | 31 Mar 2026 |
Srinivasa Raghavan Employees/Designated Employees · Public Right | Buy | 2,132 | ₹10.9 L | 31 Mar 2026 |
AAGNIKA AJAIKUMAR Promoter Group · Public Right | Buy | 19,250 | ₹98.6 L | 31 Mar 2026 |
CATALYST TRUSTEESHIP LIMITED Promoters · Public Right | Buy | 14,708 | ₹75.3 L | 31 Mar 2026 |
Hector Asia Holdings II Pte. Ltd. Promoters · Public Right | Buy | 51,18,036 | ₹262 Cr | 31 Mar 2026 |
ASMITHA AJAIKUMAR Promoter Group · Public Right | Buy | 19,250 | ₹98.6 L | 31 Mar 2026 |
Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.
Corporate actions
- rightsNot available — not reported in this filing
Rights 1:17 @ Premium Rs 502/-
2 Mar 2026ex-date - otherNot available — not reported in this filing
Annual General Meeting
22 Sept 2022ex-date - otherNot available — not reported in this filing
Annual General Meeting
23 Sept 2021ex-date - otherNot available — not reported in this filing
Annual General Meeting
19 Sept 2019ex-date - otherNot available — not reported in this filing
Annual General Meeting
19 Sept 2018ex-date - otherNot available — not reported in this filing
Annual General Meeting
3 Aug 2017ex-date - otherNot available — not reported in this filing
Annual General Meeting
22 Sept 2016ex-date
Company announcements
Pursuant to Regulation 30 of SEBI Listing Regulations, we would like to inform you that Healthcare Global (Kenya) Private Limited, a step-down subsidiary of the Company has today, i.e., ....
Intimation regarding closure of Trading Window of the Company for the quarter and half year ending September 30, 2026.
Scrutinizer's Report and Voting Results for the agenda(s) listed in the Notice of 28th Annual General Meeting of the Company.
Intimation regarding summary of proceedings of 28th Annual General Meeting of the Company.
Intimation of Schedule of Analyst/Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure requirements), Regulations 2015
Intimation of Schedule of meetings with Institutional Investors at Mumbai.
The Nomination and Remuneration Committee of the Board of Directors of the Company, at its meeting held today, i.e., September 09, 2026, has approved grant of Employee Stock Options to ....
Please note that letters are being dispatched to the Members of the Company containing web link and path of Integrated Annual Report for Financial Year 2025-26.
Newspaper advertisement pertaining to dispatch of 28th Annual General Meeting and Integrated Annual Report for FY 2025-26.
Please find enclosed the Notice of 28th Annual General Meeting and Integrated Annual Report of the Company for FY 2025-26.
Please find enclosed the Integrated Annual Report of the Company for FY 2025-26.
Please find enclosed the Business Responsibility and Sustainability Report ("BRSR") of the Company for FY 2026.
Newspaper advertisement pertaining to Notice of Annual General Meeting in accordance with MCA General Circular No. 20/2020 dated May 05, 2020.
Please find attached herewith the Transcript of Earnings Call held on August 07, 2026, with Analysts/Investors to discuss the Unaudited Financial Results (Standalone and Consolidated) of ....
Newspaper Advertisement of Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026, approved at the meeting of Board of Directors held ....
Filed with BSE (scrip 539787); the last 45 days. Documents open at bseindia.com.
SEBI filings & orders
From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.
Buybacks, open offers & rights issues
- Open offer
HealthCare Global Enterprises Limited
24 Feb 2025Read on SEBI - Open offer
HealthCare Global Enterprises Limited
5 Jun 2020Read on SEBI
Documents
Annual reports
Earnings calls
- Nov 2026TranscriptSlidesRecording
- Aug 2026TranscriptSlidesRecording
- May 2026TranscriptSlidesRecording
- Feb 2026TranscriptSlides
- Feb 2026Slides
- Dec 2025TranscriptSlidesRecording
Credit ratings
- Rating update · 25 Mar from icra
- Rating update · 7 Jan from care
- Rating update · 5 Mar 2025 from icra
- Rating update · 4 Mar 2025 from care
- Rating update · 10 Jan 2025 from care
- Rating update · 31 Dec 2024 from icra
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 6 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Healthcare Global Enterprises: common questions
Answered from the figures on this page.